Translational Molecular Investigations in Oncology: From Dysregulated Expression to Clinical Utility

The field of oncology is currently undergoing a transformation driven by high-throughput proteomics, genomics, and advanced single-cell technologies. These innovations have empowered researchers to systematically characterize and quantify molecular alterations across tumor cells, the tumor microenvironment, and various biofluids. Recent evidence demonstrates that integrative multi-omics approaches yield unprecedented insights into cancer biology, uncovering signatures linked to disease onset, tumor heterogeneity, immune modulation, prognosis, and response to therapy. Despite these strides, significant challenges remain in translating comprehensive molecular profiles into clinically actionable strategies, consolidating multi-omics data across diverse platforms, and addressing the complexities of tumor and microenvironmental heterogeneity.This Research Topic aims to highlight cutting-edge translational advances at the interface of proteogenomics and multi-omics in oncology. The primary objective is to foster original research and critical reviews that unravel molecular mechanisms of cancer through integrative analyses of genomic, transcriptomic, proteomic, and epigenomic data, with a focus on their clinical impact. Key questions include how multi-omics data inform disease classification and stratification, the identification of robust biomarkers from tissue and liquid biopsies, and the development of predictive models for therapy response, resistance, and patient outcomes. The Research Topic also seeks to promote methodological and computational innovations that bridge the gap between data generation and clinical translation.This Research Topic encompasses a broad yet defined range of studies that apply, develop, or validate integrative multi-omics approaches in cancer research, with an emphasis on clinical relevance and practical utility. We welcome original research articles and comprehensive reviews, particularly those addressing (but not limited to) the following themes:- Identification and clinical validation of multi-omic cancer biomarkers from tissue and liquid biopsies (including circulating tumor DNA/RNA, proteins, extracellular vesicles, and non-coding RNAs).- Elucidation of tumor heterogeneity, clonal dynamics, and cellular interactions via single-cell and bulk multi-omics.- Computational pipelines, data integration frameworks, and methodological advances in multi-omics analytics.- Cross-compartmental molecular communication between tumor cells and the microenvironment.- Translational case studies linking molecular profiles with disease classification, prognosis, personalization of therapy, and treatment resistance.- Application and benchmarking of emerging technologies for comprehensive molecular profiling in oncology.- Biomarker discovery using system biology approaches.Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope of this Research Topic. Topic editors: Anil Tomar, Dhruv Kumar, Ratnakar Singh Source: https://www.frontiersin.org/research-topics/78479/translational-molecular-investigations-in-oncology-from-dysregulated-expression-to-clinical-utility